Question Title

* 1. I am a

Question Title

* 2. I work with

Question Title

* 3. I  live and work

Question Title

* 4. It is being reported that Merck will be discontinuing most strengths of Temozolomide and is ending its Patient Assistant Program. What is/are the most common strength(s) of Temozolomide you prescribe?  (Check all that apply)

Question Title

* 5. Do you have patients that rely on the Patient Assistance Program?

Question Title

* 6. Has the discontinuation been communicated to these patients by Merck?

Question Title

* 7. Do you view there to be widely available alternatives (generics) to Temozolomide?  

Question Title

* 8. Do you anticipate further challenges for patients?

Question Title

* 9. Is there anything else, or specific anecdotes, regarding Merck’s discontinuation of Temozolomide production that could be helpful in advocacy efforts on Capitol Hill? 

Question Title

* 10. Previously, we asked SNO members about their experience with Lomustine (Gleostine) price hikes and shared this information with legislators in Washington, DC. We’re seeking to update our records in case there were recent changes in status.  In the last 6 months, which of the following issues have you personally encountered in prescribing Lomustine (Gleostine) to patients? (Check all that apply)

Question Title

* 11. Is there any new information regarding pricing of Lomustine or specific anecdotes from your patient care that may be helpful in sharing with legislators on Capitol Hill who are working on the issue?

0 of 11 answered
 

T